CLAIMS

1. An anti-C5 antibody for use in a method of treating or preventing a C5-related disease in a subject, wherein the method comprises the consecutive steps of:
   (a) intravenously administering a loading dose of 1500 mg of the anti-C5 antibody to the subject once, followed by subcutaneously administering at least one loading dose of 340 mg of the anti-C5 antibody to the subject; and
   (b) subcutaneously administering at least one maintenance dose of 1020 mg of the anti-C5 antibody to the subject.

2. The anti-C5 antibody for use according to claim 1, wherein the subcutaneously administered loading dose of 340 mg of the antibody is administered at least once to the subject 1 day to 3 weeks after the start of the intravenous administration of the anti-C5 antibody.

3. The anti-C5 antibody for use according to claim 2, wherein the subcutaneously administered loading dose of 340 mg of the antibody is administered once to the subject 1 day after the start of the intravenous administration of the anti-C5 antibody.

4. The anti-C5 antibody for use according to claim 2 or claim 3, wherein at least one additional loading dose of 340 mg of the anti-C5 antibody is subcutaneously administered to the subject 1 week or 2 weeks after the start of the intravenous administration of the anti-C5 antibody.

5. The anti-C5 antibody for use according to any one of claims 2 to 4, wherein an additional loading dose of 340 mg of the anti-C5 antibody is subcutaneously administered to the subject 1 week and 2 weeks after the start of the intravenous administration of the anti-C5 antibody once weekly.

6. The anti-C5 antibody for use according to any one of claims 1 to 4, wherein at least one maintenance dose of 1020 mg of the anti-C5 antibody is subcutaneously administered to the subject 4 weeks after the start of the intravenous administration of the anti-C5 antibody.

7. The anti-C5 antibody for use according to claim 6, wherein the maintenance dose of 1020 mg of the anti-C5 antibody is subcutaneously administered once to the subject 4 weeks after the start of the intravenous administration of the anti-C5 antibody.

8. The anti-C5 antibody for use according to claim 6 or claim 7, wherein the subcutaneous administration of a maintenance dose of 1020 mg of the anti-C5 antibody to the subject is repeated several times with time intervals of at least 4 weeks.

9. The anti-C5 antibody for use according to any one of claims 1 to 8, wherein the method is carried out by the following administration steps:
   (i) intravenously administering a loading dose of 1500 mg of the anti-C5 antibody to the subject once;
   (ii) subcutaneously administering a loading dose of 340 mg of the anti-C5 antibody to the subject 1 day after the start of the intravenous administration of the anti-C5 antibody;
   (iii) subcutaneously administering a loading dose of 340 mg of the anti-C5 antibody to the subject 1 week, 2 weeks and 3 weeks after the start of the intravenous administration of the anti-C5 antibody once weekly;
   (iv) subcutaneously administering a maintenance of 1020 mg of the anti-C5 antibody to the subject 4 weeks after the start of the intravenous administration of the anti-C5 antibody; and
   (v) repeating step (iv) several times with time intervals of 4 weeks.

10. The anti-C5 antibody for use according to any one of claims 1 to 9, wherein the subject received prior treatment with at least one pharmacological product useful for the treatment or prevention of the C5-related disease, wherein the

intravenously administered loading dose of 1500 mg of the anti-C5 antibody is administered to the subject after the final dose of the pharmacological product.

11. The anti-C5 antibody for use according to claim 10, wherein the intravenously administered loading dose of 1500 mg of the anti-C5 antibody is administered to the subject on the third day or after 3 days after administration of the final dose of the pharmacological product.

12. The anti-C5 antibody for use according to claim 10 or claim 11, wherein the pharmacological product comprises an siRNA targeting C5 mRNA, or an anti-C5 antibody which is different from the anti-C5 antibody comprised in the composition for subcutaneous or intravenous injection.

13. The anti-C5 antibody for use according to any one of claims 10 to 12, wherein the pharmacological product comprises Eculizumab, Ravulizumab or variants thereof.

14. The anti-C5 antibody for use according to any one of claims 1 to 13, wherein the subject has a body weight of equal or greater than 100 kg.

15. The anti-C5 antibody for use according to any one of claims 1 to 14, wherein the anti-C5 antibody concentration determined in a biological sample of said subject is 100 µg/ml or more.

16. The anti-C5 antibody for use according to any one of claims 1 to 14, wherein the hemolytic activity determined in a biological sample of said subject is less than 10 U/mL.

17. The anti-C5 antibody for use according to claim 15 or claim 16, wherein the biological sample is a blood sample, preferably a red-blood sample.

18. The anti-C5 antibody for use according to any one of claims 1 to 17, wherein the anti-C5 antibody is Crovalimab.

19. The anti-C5 antibody for use according to any one of claims 1 to 18, wherein the C5-related disease is selected from a group consisting of paroxysmal nocturnal hemoglobinuria (PNH), rheumatoid arthritis (RA), lupus nephritis, ischemia-reperfusion injury, atypical hemolytic uremic syndrome (aHUS), dense deposit disease (DDD), macular degeneration, hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, thrombotic thrombocytopenic purpura (TTP), spontaneous fetal loss, Pauci-immune vasculitis, epidermolysis bullosa, recurrent fetal loss, multiple sclerosis (MS), traumatic brain injury, an injury resulting from myocardial infarction, cardiopulmonary bypass or hemodialysis, refractory generalized myasthenia gravis (gMG), and neuromyelitis optica (NMO).